Nalaganje...
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients
OBJECTIVE: To evaluate total and out-of-pocket costs for poly(ADP-ribose) polymerase (PARP) inhibitors and differences based on insurance characteristics. METHODS: We identified ovarian cancer patients who were prescribed niraparib, olaparib, or rucaparib from the MarketScan (2014–2017) and Surveill...
Shranjeno v:
| izdano v: | Gynecol Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7902421/ https://ncbi.nlm.nih.gov/pubmed/33375989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.12.015 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|